Investor: ARCH Venture Partners
Syndex Bio has secured £11.5 million in Seed funding led by ARCH Venture Partners. Summary of transaction details: Value: £11.5 million Sector: Healthcare & Biotech Advisor: N/A Key Entities: Syndex Bio, ARCH Venture Partners Location: Cambridge, UK Note: This investment will enable Syndex Bio to further develop its proprietary mcPCR platform, advancing next-generation molecular diagnostics.
Sign in to view financial history
Sign in to view directors and officers
Sign in to view company news
